<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04482439</url>
  </required_header>
  <id_info>
    <org_study_id>TN-20-001</org_study_id>
    <nct_id>NCT04482439</nct_id>
  </id_info>
  <brief_title>Evaluation of Vision After Vivity IOL Implantation With a Target of Slight Myopia in the Non-dominant Eye</brief_title>
  <official_title>Evaluation of Quality of Vision and Visual Outcomes With Bilateral Implantation of the AcrySof® Vivity Intraocular Lens With a Target of Slight Myopia in the Non-dominant Eye</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Newsom Eye &amp; Laser Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Newsom Eye &amp; Laser Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective is to assess binocular distance-corrected near (40 cm) visual acuity of&#xD;
      patients after uneventful cataract surgery with bilateral implantation of the AcrySof® Vivity&#xD;
      Intraocular lens (IOL) when the non-dominant eye is targeted for slight myopia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a single-arm unmasked clinical evaluation study of binocular distance-corrected&#xD;
      near (40 cm) visual acuity, when the non-dominant eye is targeted for slight myopia, after&#xD;
      successful bilateral cataract surgery. Subjects will be assessed pre-operatively, operatively&#xD;
      and at 1 day, 1 month and 3 months post-operatively. Clinical evaluations will include&#xD;
      administration of a visual disturbance questionnaire (QUVID), patient-reported spectacle&#xD;
      independence questionnaire (PRSIQ), and a satisfaction questionnaire (IOLSAT), as well as&#xD;
      measurement of bilateral visual acuity and manifest refraction.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 17, 2020</start_date>
  <completion_date type="Actual">June 10, 2021</completion_date>
  <primary_completion_date type="Actual">June 10, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>This study is a single-arm unmasked clinical evaluation study of binocular distance-corrected near (40 cm) visual acuity, when the non-dominant eye is targeted for slight myopia, after successful bilateral cataract surgery.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Binocular near visual acuity</measure>
    <time_frame>3 months postop</time_frame>
    <description>binocular distance-corrected near (40 cm) visual acuity at 3 months postoperative.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Prediction accuracy</measure>
    <time_frame>1 and 3 months postop</time_frame>
    <description>Percentage of eyes with postoperative refractive accuracy within 0.5D of target</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Spectacle independence</measure>
    <time_frame>3 months postop</time_frame>
    <description>Percent of all patients who never or rarely wear spectacles for distance, intermediate or near vision 3 months postop (based on the Patient-Reported Spectacle Independence Questionnaire - &quot;a little of the time&quot; or &quot;none of the time&quot;)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient satisfaction</measure>
    <time_frame>3 months postop</time_frame>
    <description>Patient satisfaction questionnaire scores (IOLSAT proprietary questionnaire), based on a 0-4 scale, with lower being better.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual disturbances</measure>
    <time_frame>3 months postop</time_frame>
    <description>Questionnaire for Visual Disturbance scores (QUVID proprietary questionnaire), based on a 0-4 scale with lower being better.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Manifest refraction</measure>
    <time_frame>1 and 3 months postop</time_frame>
    <description>Manifest refraction (residual spherical equivalent refraction, residual sphere, and residual astigmatism)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Uncorrected distance visual acuity</measure>
    <time_frame>1 and 3 months postop</time_frame>
    <description>Bilateral uncorrected distance visual acuity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Uncorrected intermediate visual acuity</measure>
    <time_frame>1 and 3 months postop</time_frame>
    <description>Bilateral uncorrected visual acuity at 66 cm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Uncorrected near visual acuity</measure>
    <time_frame>1 and 3 months postop</time_frame>
    <description>Bilateral uncorrected distance visual acuity at 40 cm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Corrected distance visual acuity</measure>
    <time_frame>1 and 3 months postop</time_frame>
    <description>Bliateral corrected distance visual acuity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Corrected intermediate visual acuity</measure>
    <time_frame>1 and 3 months postop</time_frame>
    <description>Bliateral corrected visual acuity at 66 cm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Corrected near visual acuity</measure>
    <time_frame>1 and 3 months postop</time_frame>
    <description>Bliateral corrected visual acuity at 40 cm</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">35</enrollment>
  <condition>Cataract</condition>
  <arm_group>
    <arm_group_label>Vivity mini-monovision</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will have bilateral Vivity IOL implanted, with a target of slight myopia in the non-dominant eye.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Vivity Extended Depth of Focus intraocular lens (IOL)</intervention_name>
    <description>Bilateral implantation of the Vivity lens after cataract surgery, with slight myopia planned in the non-dominant eye.</description>
    <arm_group_label>Vivity mini-monovision</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  • Presenting for uncomplicated bilateral cataract surgery and have an interest in&#xD;
             spectacle independence using an EDF IOL&#xD;
&#xD;
               -  Meet the requirements for on-label implantation of the EDF IOL&#xD;
&#xD;
               -  Gender: Males and Females.&#xD;
&#xD;
               -  Age: 40 or older.&#xD;
&#xD;
               -  Willing and able to provide written informed consent for participation in the&#xD;
                  study.&#xD;
&#xD;
               -  Willing and able to comply with scheduled visits and other study procedures.&#xD;
&#xD;
               -  Have good ocular health, with no pathology that compromises visual acuity&#xD;
                  (outside of residual refractive error and cataract)&#xD;
&#xD;
               -  Have regular corneal astigmatism with a magnitude that can be treated with a&#xD;
                  non-toric IOL or toric IOL.&#xD;
&#xD;
               -  Have 20/32 (0.2 logMAR) or better potential acuity in both eyes&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  • Irregular astigmatism (e.g. keratoconus)&#xD;
&#xD;
               -  Corneal pathology (e.g. scar, dystrophy, pterygium, severe dry eye)&#xD;
&#xD;
               -  Monocular status (e.g. amblyopia)&#xD;
&#xD;
               -  Previous radial keratotomy, corneal refractive surgery or other corneal surgery&#xD;
                  (e.g. corneal transplant, DSAEK, lamellar keratoplasty)&#xD;
&#xD;
               -  Previous anterior or posterior chamber surgery (e.g., vitrectomy, laser&#xD;
                  iridotomy)&#xD;
&#xD;
               -  Diabetic retinopathy&#xD;
&#xD;
               -  Macular pathology (e.g. ARMD, ERM)&#xD;
&#xD;
               -  History of retinal detachment&#xD;
&#xD;
               -  Subjects who have an unstable acute or chronic disease or illness that would&#xD;
                  confound the results of this investigation (e.g., immunocompromised, connective&#xD;
                  tissue disease, clinically significant atopic disease, diabetes, and any other&#xD;
                  such disease or illness), that are known to affect postoperative visual acuity.&#xD;
&#xD;
               -  Participation in any investigational drug or device trial within the previous 30&#xD;
                  days prior to the start date of this trial (or currently participating).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Newsom, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Newsom Eye &amp; Laser Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Newsom Eye and Laser Center</name>
      <address>
        <city>Sebring</city>
        <state>Florida</state>
        <zip>33870</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 17, 2020</study_first_submitted>
  <study_first_submitted_qc>July 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 22, 2020</study_first_posted>
  <last_update_submitted>August 22, 2021</last_update_submitted>
  <last_update_submitted_qc>August 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cataract</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

